CARM1 and gastric cancer: In addition, although detailed studies and further validation are needed to assess their clinical significance, we propose that LRRFIP2 variants (2 or 3) may serve as potential biomarkers for gastric cancer liver metastasis and as therapeutic biomarkers for CARM1 inhibitors.